Literature DB >> 31092985

Pathogenic and Therapeutic Role of H3K4 Family of Methylases and Demethylases in Cancers.

Aman Kumar1, Niti Kumari1, Nayudu Nallabelli2, Rajendra Prasad1.   

Abstract

Histone modifications occupy an essential position in the epigenetic landscape of the cell, and their alterations have been linked to cancers. Histone 3 lysine 4 (H3K4) methylation has emerged as a critical epigenetic cue for the regulation of gene transcription through dynamic modulation by several H3K4 methyltransferases (writers) and demethylases (erasers). Any disturbance in the delicate balance of writers and erasers can result in the mis-regulation of H3K4 methylation, which has been demonstrated in several human cancers. Therefore, H3K4 methylation has been recognized as a putative therapeutic or prognostic tool and drug trials of different inhibitors of this process have demonstrated promising results. Henceforth, more detailed knowledge of H3K4 methylation is utmost important for elucidating the complex cellular processes, which might help in improving the disease outcome. The primary focus of this review will be directed on deciphering the role of H3K4 methylation along with its writers/erasers in different cancers.

Entities:  

Keywords:  Cancer; H3K4 methylation; Histone demethylases; Histone methyltransferases; Prognosis; Therapeutics

Year:  2019        PMID: 31092985      PMCID: PMC6486936          DOI: 10.1007/s12291-019-00828-x

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  118 in total

1.  Deletion of Y-chromosome specific genes in human prostate cancer.

Authors:  G Perinchery; M Sasaki; A Angan; V Kumar; P Carroll; R Dahiya
Journal:  J Urol       Date:  2000-04       Impact factor: 7.450

Review 2.  Translating the histone code.

Authors:  T Jenuwein; C D Allis
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

3.  Crystal structure and functional analysis of the histone methyltransferase SET7/9.

Authors:  Jonathan R Wilson; Chun Jing; Philip A Walker; Stephen R Martin; Steven A Howell; G Michael Blackburn; Steven J Gamblin; Bing Xiao
Journal:  Cell       Date:  2002-10-04       Impact factor: 41.582

4.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias.

Authors:  Chi Wai So; Min Lin; Paul M Ayton; Everett H Chen; Michael L Cleary
Journal:  Cancer Cell       Date:  2003-08       Impact factor: 31.743

5.  NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines.

Authors:  P O Angrand; F Apiou; A F Stewart; B Dutrillaux; R Losson; P Chambon
Journal:  Genomics       Date:  2001-05-15       Impact factor: 5.736

6.  PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?

Authors:  Angela Barrett; Bente Madsen; John Copier; Pei Juan Lu; Lucienne Cooper; Angelo G Scibetta; Joy Burchell; Joyce Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  2002-10-20       Impact factor: 7.396

Review 7.  Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins.

Authors:  P M Ayton; M L Cleary
Journal:  Oncogene       Date:  2001-09-10       Impact factor: 9.867

8.  SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.

Authors:  Ryuji Hamamoto; Yoichi Furukawa; Masashi Morita; Yuko Iimura; Fabio Pittella Silva; Meihua Li; Ryuichiro Yagyu; Yusuke Nakamura
Journal:  Nat Cell Biol       Date:  2004-07-04       Impact factor: 28.824

9.  MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression.

Authors:  Lih-Wen Deng; Isaac Chiu; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-12       Impact factor: 11.205

Review 10.  ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia.

Authors:  E Canaani; T Nakamura; T Rozovskaia; S T Smith; T Mori; C M Croce; A Mazo
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.